Functional autoantibodies in systemic sclerosis

Seminars in Immunopathology

Volumn 37, Issue 5, 2015, Pages 529-542

  Günther, Jeannine ^a,b   Rademacher, Judith ^a,b   van Laar, Jakob M ^c   Siegert, Elise ^a   Riemekasten, Gabriela ^a,b,d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Disease pathogenesis; Functional autoantibodies; Molecular targets; Review; Systemic sclerosis

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; AUTOANTIBODY; CELL ANTIBODY; ENDOTHELIAL CELL ANTIBODY; ENDOTHELIN A RECEPTOR; ESTROGEN RECEPTOR; FIBROBLAST ANTIBODY; MUSCARINIC M3 RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG;

AUTOIMMUNITY; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC SCLEROSIS; IMMUNOLOGY;

AUTOANTIBODIES; HUMANS; SCLERODERMA, SYSTEMIC;

EID: 84940900420     PISSN: 18632297     EISSN: 18632300     Source Type: Journal    
DOI: 10.1007/s00281-015-0513-5     Document Type: Review

References (112)

1. Mehra S, Walker J, Patterson K, Fritzler MJ (2013) Autoantibodies in systemic sclerosis. Autoimmun Rev 12(3):340–354. doi:10.1016/j.autrev.2012.05.011
2. Klein-Weigel P, Opitz C, Riemekasten G (2011) Systemic sclerosis—a systematic overview: part 1—disease characteristics and classification, pathophysiologic concepts, and recommendations for diagnosis and surveillance. VASA Z Gefasskrankheiten 40(1):6–19. doi:10.1024/0301-1526/a000065
3. Gleicher N, Barad D, Weghofer A (2007) Functional autoantibodies, a new paradigm in autoimmunity? Autoimmun Rev 7(1):42–45. doi:10.1016/j.autrev.2007.06.001
4. Smilek DE, St Clair EW (2015) Solving the puzzle of autoimmunity: critical questions. F1000prime reports 7:17. doi:10.12703/P7-17
5. Perricone C, Agmon-Levin N, Ceccarelli F, Valesini G, Anaya JM, Shoenfeld Y (2013) Genetics and autoantibodies. Immunol Res 56(2–3):206–219. doi:10.1007/s12026-013-8396-9
6. Grimaldi CM, Cleary J, Dagtas AS, Moussai D, Diamond B (2002) Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest 109(12):1625–1633. doi:10.1172/JCI14873
7. Lunardi C, Tinazzi E, Bason C, Dolcino M, Corrocher R, Puccetti A (2008) Human parvovirus B19 infection and autoimmunity. Autoimmun Rev 8(2):116–120. doi:10.1016/j.autrev.2008.07.005
8. Ercolini AM, Miller SD (2009) The role of infections in autoimmune disease. Clin Exp Immunol 155(1):1–15. doi:10.1111/j.1365-2249.2008.03834.x
9. Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y (2009) Infections and autoimmunity—friends or foes? Trends Immunol 30(8):409–414. doi:10.1016/j.it.2009.05.005
10. Bogdanos DP, Smyk DS, Invernizzi P, Rigopoulou EI, Blank M, Pouria S, Shoenfeld Y (2013) Infectome: a platform to trace infectious triggers of autoimmunity. Autoimmun Rev 12(7):726–740. doi:10.1016/j.autrev.2012.12.005
11. Pollard KM (2015) Environment, autoantibodies, and autoimmunity. Front Immunol 6:60. doi:10.3389/fimmu.2015.00060
12. Stepan H, Wallukat G, Schultheiss HP, Faber R, Walther T (2007) Is parvovirus B19 the cause for autoimmunity against the angiotensin II type receptor? J Reprod Immunol 73(2):130–134. doi:10.1016/j.jri.2006.08.084
13. van Venrooij WJ, Zendman AJ, Pruijn GJ (2006) Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev 6(1):37–41. doi:10.1016/j.autrev.2006.03.008
14. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349(16):1526–1533. doi:10.1056/NEJMoa021933
15. Weiner ES, Hildebrandt S, Senecal JL, Daniels L, Noell S, Joyal F, Roussin A, Earnshaw W, Rothfield NF (1991) Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud’s disease. A prospective study. Arthritis Rheum 34(1):68–77
16. Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35(1):35–42. doi:10.1016/j.semarthrit.2005.03.005
17. Senecal JL, Henault J, Raymond Y (2005) The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis (scleroderma). J Rheumatol 32(9):1643–1649
18. Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Muller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 66(6):754–763. doi:10.1136/ard.2006.062901
19. Meier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP, Allanore Y, Distler O, Riemekasten G, Valentini G, Muller-Ladner U, Co-authors E (2012) Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 71(8):1355–1360. doi:10.1136/annrheumdis-2011-200742
20. Henault J, Robitaille G, Senecal JL, Raymond Y (2006) DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 54(3):963–973. doi:10.1002/art.21646
21. Arcand J, Robitaille G, Koenig M, Senecal JL, Raymond Y (2012) The autoantigen DNA topoisomerase I interacts with chemokine receptor 7 and exerts cytokine-like effects on dermal fibroblasts. Arthritis Rheum 64(3):826–834. doi:10.1002/art.33377
22. Hamaguchi Y, Kodera M, Matsushita T, Hasegawa M, Inaba Y, Usuda T, Kuwana M, Takehara K, Fujimoto M (2015) Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase iii autoantibodies. Arthritis Rheumatol 67(4):1045–1052. doi:10.1002/art.38994
23. Senecal JL, Ichiki S, Girard D, Raymond Y (1993) Autoantibodies to nuclear lamins and to intermediate filament proteins: natural, pathologic or pathogenic? J Rheumatol 20(2):211–219
24. Naparstek Y, Plotz PH (1993) The role of autoantibodies in autoimmune disease. Annu Rev Immunol 11:79–104. doi:10.1146/annurev.iy.11.040193.000455
25. Wallukat G, Schimke I (2014) Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases. Semin Immunopathol 36(3):351–363. doi:10.1007/s00281-014-0425-9
26. Roitt IM, Doniach D (1957) Auto-immunization in thyroid diseases. Proc R Soc Med 50(11):958–961
27. Smart GA (1959) Discussion on the importance of auto-antibody disease in clinical medicine; introduction: renal and thyroid diseases. Proc R Soc Med 52(6):437–440
28. Islam MN, Briones-Urbina R, Bako G, Farid NR (1983) Both TSH and thyroid-stimulating antibody of Graves’ disease bind to an Mr 197,000 holoreceptor. Endocrinology 113(1):436–438. doi:10.1210/endo-113-1-436
29. de Bruin TW, van der Heide D (1984) Anti-TSH receptor antibodies in Graves’ disease modulate the kinetic behaviour of autologous thyroid TSH receptors. Evidence of the IgG-induced cross-linkage of autologous TSH receptors. Acta Endocrinol (Copenh) 105(3):330–340
30. Huber GK, Safirstein R, Neufeld D, Davies TF (1991) Thyrotropin receptor autoantibodies induce human thyroid cell growth and c-fos activation. J Clin Endocrinol Metab 72(5):1142–1147. doi:10.1210/jcem-72-5-1142
31. Luft FC (2013) Activating autoantibodies and cardiovascular disease. Physiology 28(4):254–261. doi:10.1152/physiol.00014.2013
32. McLachlan SM, Rapoport B (2013) Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa. Thyroid Off J Am Thyroid Assoc 23(1):14–24. doi:10.1089/thy.2012.0374
33. Hebert TE, Moffett S, Morello JP, Loisel TP, Bichet DG, Barret C, Bouvier M (1996) A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J Biol Chem 271(27):16384–16392
34. Hoebeke J (2001) Molecular mechanisms of anti-G-protein-coupled receptor autoantibodies. Autoimmunity 34(3):161–164
35. Limas CJ, Goldenberg IF, Limas C (1990) Influence of anti-beta-receptor antibodies on cardiac adenylate cyclase in patients with idiopathic dilated cardiomyopathy. Am Heart J 119(6):1322–1328
36. Staudt A, Eichler P, Trimpert C, Felix SB, Greinacher A (2007) Fc(gamma) receptors IIa on cardiomyocytes and their potential functional relevance in dilated cardiomyopathy. J Am Coll Cardiol 49(16):1684–1692. doi:10.1016/j.jacc.2006.11.051
37. Pierce KL, Premont RT, Lefkowitz RJ (2002) Seven-transmembrane receptors. Nat Rev Mol Cell Biol 3(9):639–650. doi:10.1038/nrm908
38. Podlowski S, Luther HP, Morwinski R, Muller J, Wallukat G (1998) Agonistic anti-beta1-adrenergic receptor autoantibodies from cardiomyopathy patients reduce the beta1-adrenergic receptor expression in neonatal rat cardiomyocytes. Circulation 98(22):2470–2476
39. Dragun D, Distler JH, Riemekasten G, Distler O (2009) Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology. Arthritis Rheum 60(4):907–911. doi:10.1002/art.24364
40. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A, Avvedimento EV, Gabrielli A (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354(25):2667–2676. doi:10.1056/NEJMoa052955
41. Gabrielli A, Svegliati S, Moroncini G, Avvedimento EV (2007) Pathogenic autoantibodies in systemic sclerosis. Curr Opin Immunol 19(6):640–645. doi:10.1016/j.coi.2007.11.004
42. Classen JF, Henrohn D, Rorsman F, Lennartsson J, Lauwerys BR, Wikstrom G, Rorsman C, Lenglez S, Franck-Larsson K, Tomasi JP, Kampe O, Vanthuyne M, Houssiau FA, Demoulin JB (2009) Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum 60(4):1137–1144. doi:10.1002/art.24381
43. Loizos N, Lariccia L, Weiner J, Griffith H, Boin F, Hummers L, Wigley F, Kussie P (2009) Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera. Arthritis Rheum 60(4):1145–1151. doi:10.1002/art.24365
44. Kurasawa K, Arai S, Owada T, Maezawa R, Kumano K, Fukuda T (2010) Autoantibodies against platelet-derived growth factor receptor alpha in patients with systemic lupus erythematosus. Mod Rheumatol Japan Rheum Assoc 20(5):458–465. doi:10.1007/s10165-010-0310-x
45. Moroncini G, Grieco A, Nacci G, Paolini C, Tonnini C, Pozniak KN, Cuccioloni M, Mozzicafreddo M, Svegliati S, Angeletti M, Kazlauskas A, Avvedimento EV, Funaro A, Gabrielli A (2015) Epitope specificity determines pathogenicity and detectability of anti-PDGFRalpha autoantibodies in systemic sclerosis. Arthritis Rheumatol. doi:10.1002/art.39125
46. Yang Y, Yuzawa S, Schlessinger J (2008) Contacts between membrane proximal regions of the PDGF receptor ectodomain are required for receptor activation but not for receptor dimerization. Proc Natl Acad Sci U S A 105(22):7681–7686. doi:10.1073/pnas.0802896105
47. Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141(7):1117–1134. doi:10.1016/j.cell.2010.06.011
48. Ortona E, Pierdominici M, Berstein L (2014) Autoantibodies to estrogen receptors and their involvement in autoimmune diseases and cancer. J Steroid Biochem Mol Biol 144(Pt B):260–267. doi:10.1016/j.jsbmb.2014.07.004
49. Grimaldi CM, Hicks R, Diamond B (2005) B cell selection and susceptibility to autoimmunity. J Immunol 174(4):1775–1781
50. Ueda K, Karas RH (2013) Emerging evidence of the importance of rapid, non-nuclear estrogen receptor signaling in the cardiovascular system. Steroids 78(6):589–596. doi:10.1016/j.steroids.2012.12.006
51. Kovats S (2015) Estrogen receptors regulate innate immune cells and signaling pathways. Cell Immunol 294(2):63–69. doi:10.1016/j.cellimm.2015.01.018
52. Pierdominici M, Maselli A, Colasanti T, Giammarioli AM, Delunardo F, Vacirca D, Sanchez M, Giovannetti A, Malorni W, Ortona E (2010) Estrogen receptor profiles in human peripheral blood lymphocytes. Immunol Lett 132(1–2):79–85. doi:10.1016/j.imlet.2010.06.003
53. Mudarris A, Peck EJ Jr (1987) Human anti-estrogen receptor antibodies: assay, characterization, and age- and sex-related differences. J Clin Endocrinol Metab 64(2):246–254. doi:10.1210/jcem-64-2-246
54. Colasanti T, Maselli A, Conti F, Sanchez M, Alessandri C, Barbati C, Vacirca D, Tinari A, Chiarotti F, Giovannetti A, Franconi F, Valesini G, Malorni W, Pierdominici M, Ortona E (2012) Autoantibodies to estrogen receptor alpha interfere with T lymphocyte homeostasis and are associated with disease activity in systemic lupus erythematosus. Arthritis Rheum 64(3):778–787. doi:10.1002/art.33400
55. Giovannetti A, Maselli A, Colasanti T, Rosato E, Salsano F, Pisarri S, Mezzaroma I, Malorni W, Ortona E, Pierdominici M (2013) Autoantibodies to estrogen receptor alpha in systemic sclerosis (SSc) as pathogenetic determinants and markers of progression. PloS One 8(9):e74332. doi:10.1371/journal.pone.0074332
56. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC (1999) Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 103(7):945–952. doi:10.1172/JCI4106
57. Xia Y, Kellems RE (2009) Is preeclampsia an autoimmune disease? Clin Immunol 133(1):1–12. doi:10.1016/j.clim.2009.05.004
58. Fu ML, Herlitz H, Schulze W, Wallukat G, Micke P, Eftekhari P, Sjogren KG, Hjalmarson A, Muller-Esterl W, Hoebeke J (2000) Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens 18(7):945–953
59. Dragun D, Muller DN, Brasen JH, Fritsche L, Nieminen-Kelha M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, Schonemann C, Unger T, Budde K, Neumayer HH, Luft FC, Wallukat G (2005) Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 352(6):558–569. doi:10.1056/NEJMoa035717
60. Riemekasten G, Philippe A, Nather M, Slowinski T, Muller DN, Heidecke H, Matucci-Cerinic M, Czirjak L, Lukitsch I, Becker M, Kill A, van Laar JM, Catar R, Luft FC, Burmester GR, Hegner B, Dragun D (2011) Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 70(3):530–536. doi:10.1136/ard.2010.135772
61. Becker MO, Kill A, Kutsche M, Guenther J, Rose A, Tabeling C, Witzenrath M, Kuhl AA, Heidecke H, Ghofrani HA, Tiede H, Schermuly RT, Nickel N, Hoeper MM, Lukitsch I, Gollasch M, Kuebler WM, Bock S, Burmester GR, Dragun D, Riemekasten G (2014) Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med 190(7):808–817. doi:10.1164/rccm.201403-0442OC
62. Gunther J, Kill A, Becker MO, Heidecke H, Rademacher J, Siegert E, Radic M, Burmester GR, Dragun D, Riemekasten G (2014) Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients. Arthritis Res Ther 16(2):R65. doi:10.1186/ar4503
63. Kill A, Tabeling C, Undeutsch R, Kuhl AA, Gunther J, Radic M, Becker MO, Heidecke H, Worm M, Witzenrath M, Burmester GR, Dragun D, Riemekasten G (2014) Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther 16(1):R29. doi:10.1186/ar4457
64. Trojanowska M (2009) Noncanonical transforming growth factor beta signaling in scleroderma fibrosis. Curr Opin Rheumatol 21(6):623–629. doi:10.1097/BOR.0b013e32833038ce
65. LeRoy EC (1974) Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 54(4):880–889. doi:10.1172/JCI107827
66. Jimenez SA, Feldman G, Bashey RI, Bienkowski R, Rosenbloom J (1986) Co-ordinate increase in the expression of type I and type III collagen genes in progressive systemic sclerosis fibroblasts. Biochem J 237(3):837–843
67. Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, Vollmer E, Muller-Quernheim J, Zissel G (2006) A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 173(7):781–792. doi:10.1164/rccm.200509-1518OC
68. Pochetuhen K, Luzina IG, Lockatell V, Choi J, Todd NW, Atamas SP (2007) Complex regulation of pulmonary inflammation and fibrosis by CCL18. Am J Pathol 171(2):428–437. doi:10.2353/ajpath.2007.061167
69. Schupp J, Becker M, Gunther J, Muller-Quernheim J, Riemekasten G, Prasse A (2014) Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis. Eur Respir J 43(5):1530–1532. doi:10.1183/09031936.00131713
70. Koch AE, Kronfeld-Harrington LB, Szekanecz Z, Cho MM, Haines GK, Harlow LA, Strieter RM, Kunkel SL, Massa MC, Barr WG et al (1993) In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. Pathobiol J Immunopathol Mol Cell Biol 61(5–6):239–246
71. Bacman S, Perez Leiros C, Sterin-Borda L, Hubscher O, Arana R, Borda E (1998) Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptors in patients with primary Sjogren’s syndrome. Invest Ophthalmol Vis Sci 39(1):151–156
72. Patel R, Shahane A (2014) The epidemiology of Sjogren’s syndrome. Clin Epidemiol 6:247–255. doi:10.2147/CLEP.S47399
73. Goldblatt F, Gordon TP, Waterman SA (2002) Antibody-mediated gastrointestinal dysmotility in scleroderma. Gastroenterology 123(4):1144–1150
74. Singh J, Mehendiratta V, Del Galdo F, Jimenez SA, Cohen S, DiMarino AJ, Rattan S (2009) Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells. Am J Physiol Gastrointest Liver Physiol 297(6):G1206–G1213. doi:10.1152/ajpgi.00286.2009
75. Singh J, Cohen S, Mehendiratta V, Mendoza F, Jimenez SA, Dimarino AJ, Rattan S (2012) Effects of scleroderma antibodies and pooled human immunoglobulin on anal sphincter and colonic smooth muscle function. Gastroenterology 143(5):1308–1318. doi:10.1053/j.gastro.2012.07.109
76. Cavill D, Waterman SA, Gordon TP (2004) Antibodies raised against the second extracellular loop of the human muscarinic M3 receptor mimic functional autoantibodies in Sjogren’s syndrome. Scand J Immunol 59(3):261–266. doi:10.1111/j.0300-9475.2004.01395.x
77. Preuss B, Tunaru S, Henes J, Offermanns S, Klein R (2014) A novel luminescence-based method for the detection of functionally active antibodies to muscarinic acetylcholine receptors of the M3 type (mAchR3) in patients’ sera. Clin Exp Immunol 177(1):179–189. doi:10.1111/cei.12324
78. Lukitsch I, Kehr J, Chaykovska L, Wallukat G, Nieminen-Kelha M, Batuman V, Dragun D, Gollasch M (2012) Renal ischemia and transplantation predispose to vascular constriction mediated by angiotensin II type 1 receptor-activating antibodies. Transplantation 94(1):8–13. doi:10.1097/TP.0b013e3182529bb7
79. Carvalho D, Savage CO, Black CM, Pearson JD (1996) IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest 97(1):111–119. doi:10.1172/JCI118377
80. Arends SJ, Damoiseaux JG, Duijvestijn AM, Debrus-Palmans L, Vroomen M, Boomars KA, Brunner-La Rocca HP, Reutelingsperger CP, Cohen Tervaert JW, van Paassen P (2013) Immunoglobulin G anti-endothelial cell antibodies: inducers of endothelial cell apoptosis in pulmonary arterial hypertension? Clin Exp Immunol 174(3):433–440. doi:10.1111/cei.12166
81. Lunardi C, Bason C, Navone R, Millo E, Damonte G, Corrocher R, Puccetti A (2000) Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 6(10):1183–1186. doi:10.1038/80533
82. Tachibana I, Bodorova J, Berditchevski F, Zutter MM, Hemler ME (1997) NAG-2, a novel transmembrane-4 superfamily (TM4SF) protein that complexes with integrins and other TM4SF proteins. J Biol Chem 272(46):29181–29189
83. Lunardi C, Dolcino M, Peterlana D, Bason C, Navone R, Tamassia N, Beri R, Corrocher R, Puccetti A (2006) Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: a gene array approach. PLoS Med 3(1):e2. doi:10.1371/journal.pmed.0030002
84. Wolf SI, Howat S, Abraham DJ, Pearson JD, Lawson C (2013) Agonistic anti-ICAM-1 antibodies in scleroderma: activation of endothelial pro-inflammatory cascades. Vasc Pharmacol 59(1–2):19–26. doi:10.1016/j.vph.2013.05.002
85. Chizzolini C, Raschi E, Rezzonico R, Testoni C, Mallone R, Gabrielli A, Facchini A, Del Papa N, Borghi MO, Dayer JM, Meroni PL (2002) Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 46(6):1602–1613. doi:10.1002/art.10361
86. Tamby MC, Humbert M, Guilpain P, Servettaz A, Dupin N, Christner JJ, Simonneau G, Fermanian J, Weill B, Guillevin L, Mouthon L (2006) Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Eur Respir J 28(4):799–807. doi:10.1183/09031936.06.00152705
87. Terrier B, Tamby MC, Camoin L, Guilpain P, Broussard C, Bussone G, Yaici A, Hotellier F, Simonneau G, Guillevin L, Humbert M, Mouthon L (2008) Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. Am J Respir Crit Care Med 177(10):1128–1134. doi:10.1164/rccm.200707-1015OC
88. Terrier B, Tamby MC, Camoin L, Guilpain P, Berezne A, Tamas N, Broussard C, Hotellier F, Humbert M, Simonneau G, Guillevin L, Mouthon L (2010) Antifibroblast antibodies from systemic sclerosis patients bind to {alpha}-enolase and are associated with interstitial lung disease. Ann Rheum Dis 69(2):428–433. doi:10.1136/ard.2008.104299
89. Jimenez SA, Hitraya E, Varga J (1996) Pathogenesis of scleroderma. Collagen. Rheum Dis Clin N Am 22(4):647–674
90. Sato S, Hayakawa I, Hasegawa M, Fujimoto M, Takehara K (2003) Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Investig Dermatol 120(4):542–547. doi:10.1046/j.1523-1747.2003.12097.x
91. Nishijima C, Hayakawa I, Matsushita T, Komura K, Hasegawa M, Takehara K, Sato S (2004) Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 138(2):357–363. doi:10.1111/j.1365-2249.2004.02615.x
92. Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van Laar J, Ouyang J, Kozak T, Moore J, Kotter I, Chesnel V, Marmont A, Gratwohl A, Saccardi R (2010) Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 95(2):284–292. doi:10.3324/haematol.2009.013458
93. van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, Schuerwegh AJ, Marijt EW, Vonk MC, Schattenberg AV, Matucci-Cerinic M, Voskuyl AE, van de Loosdrecht AA, Daikeler T, Kotter I, Schmalzing M, Martin T, Lioure B, Weiner SM, Kreuter A, Deligny C, Durand JM, Emery P, Machold KP, Sarrot-Reynauld F, Warnatz K, Adoue DF, Constans J, Tony HP, Del Papa N, Fassas A, Himsel A, Launay D, Lo Monaco A, Philippe P, Quere I, Rich E, Westhovens R, Griffiths B, Saccardi R, van den Hoogen FH, Fibbe WE, Socie G, Gratwohl A, Tyndall A, Group EESS (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311(24):2490–2498. doi:10.1001/jama.2014.6368
94. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T, Hiepe F (2006) Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 6(10):741–750. doi:10.1038/nri1886
95. Hoyer BF, Manz RA, Radbruch A, Hiepe F (2005) Long-lived plasma cells and their contribution to autoimmunity. Ann N Y Acad Sci 1050:124–133. doi:10.1196/annals.1313.014
96. Illei GG, Cervera R, Burt RK, Doria A, Hiepe F, Jayne D, Pavletic S, Martin T, Marmont A, Saccardi R, Voskuyl AE, Farge D (2011) Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann Rheum Dis 70(12):2071–2074. doi:10.1136/ard.2010.148049
97. Humbert M, Cabane J (2003) Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatology 42(1):191–193
98. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick A, Merkel PA, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Black C (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50(12):3985–3993. doi:10.1002/art.20676
99. Tillon J, Herve F, Chevallier D, Muir JF, Levesque H, Marie I (2006) Successful treatment of systemic sclerosis-related digital ulcers and sarcoidosis with endothelin receptor antagonist (bosentan) therapy. Br J Dermatol 154(5):1000–1002. doi:10.1111/j.1365-2133.2006.07194.x
100. Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P, Stefanadis C, Mavrikakis M (2007) Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 56(6):1985–1993. doi:10.1002/art.22634
101. Ambach A, Seo W, Bonnekoh B, Gollnick H (2009) Low-dose combination therapy of severe digital ulcers in diffuse progressive systemic sclerosis with the endothelin-1 receptor antagonist bosentan and the phosphodiesterase V inhibitor sildenafil. J Dtsch Dermatol Ges J Ger Soc Dermatol: JDDG 7(10):888–891. doi:10.1111/j.1610-0387.2009.07057.x
102. Gholam P, Sehr T, Enk A, Hartmann M (2009) Successful treatment of systemic-sclerosis-related digital ulcers with a selective endothelin type A receptor antagonist (sitaxentan). Dermatology 219(2):171–173. doi:10.1159/000228318
103. Nishibu A, Sakai E, Oyama N, Yamamoto T (2012) Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis. Aust J Dermatol 53(2):e32–e33. doi:10.1111/j.1440-0960.2010.00719.x
104. Cutolo M, Ruaro B, Pizzorni C, Ravera F, Smith V, Zampogna G, Paolino S, Seriolo B, Cimmino M, Sulli A (2014) Longterm treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis. J Rheumatol 41(5):881–886. doi:10.3899/jrheum.131284
105. Chung L, Ball K, Yaqub A, Lingala B, Fiorentino D (2014) Effect of the endothelin type A-selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: results of a prospective pilot study. J Am Acad Dermatol 71(2):400–401. doi:10.1016/j.jaad.2014.04.028
106. Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, Black CM (1999) Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 42(12):2646–2655. doi:10.1002/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T
107. McQueen FM, Solanki K (2015) Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today? Rheumatology. doi:10.1093/rheumatology/keu463
108. Hohenstein B, Bornstein SR, Aringer M (2013) Immunoadsorption for connective tissue disease. Atheroscler Suppl 14(1):185–189. doi:10.1016/j.atherosclerosissup.2012.10.034
109. Hessel FP, Wegner C, Muller J, Glaveris C, Wasem J (2004) Economic evaluation and survival analysis of immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Eur J Health Econ: HEPAC: Health Econ Prev Care 5(1):58–63. doi:10.1007/s10198-003-0202-5
110. Dandel M, Wallukat G, Englert A, Hetzer R (2013) Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension. Atheroscler Suppl 14(1):203–211. doi:10.1016/j.atherosclerosissup.2012.10.029
111. Haberland A, Wallukat G, Schimke I (2011) Aptamer binding and neutralization of beta1-adrenoceptor autoantibodies: basics and a vision of its future in cardiomyopathy treatment. Trends Cardiovasc Med 21(6):177–182. doi:10.1016/j.tcm.2012.05.006
112. Haberland A, Wallukat G, Schimke I (2013) The patent situation concerning the treatment of diseases associated with autoantibodies directed against G-protein-coupled receptors. Pharm Patent Anal 2(2):231–248. doi:10.4155/ppa.12.88